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Aim
To evaluate the efficacy and safety of MMF in jo-SLE in a
multicenter study.
Methods
Medical charts of 26 pts, 25 F, 1 M, mean age at SLE diag-
nosis 12.7 yrs (range 5–18), mean age at MMF starting
15.9 yrs (range 7.5–26.8), followed in Florence, Padua,
and Messina, Italy, treated with MMF from 2004 to 2007,
were retrospectively analyzed. Clinical and laboratory
evaluation included: blood count, ESR, CRP, ANA, anti-
dsDNA, LFT, coagulation, C4, renal function, Coombs'
test, aCL, antiβ2GPI and LAC at baseline and every 6
months. Disease activity was monitored by the SLEDAI
score. Treatment duration was 24 ± 14.8 months (range
2–52). MMF (1.5–2 g/day) was started due to steroid tox-
icity (n = 9 pts), CyA toxicity (n = 5), disease activity (n =
8) or nephropathy progression despite previous immuno-
suppression (n = 4). 9/26 pts, before MMF had renal dis-
ease (7 WHO Class IIb, 1 Class III, 1 Class IV). In 5/9 MMF
was the first treatment, while 4/9 had received immuno-
suppressants.
Results
MMF was effective in reducing disease activity, steroid
sparing in 14/26 (54%), stabilizing the disease in 8 (31%)
and ineffective in 4 (15%). In 9/13 (69%) without renal
involvement a good response was registered. Among pts
with renal involvement, MMF was effective in 5/13
(38%), partially effective in 4 (31%) and ineffective in 4
(31%). 2 pts stopped MMF for diarrhoea and abdominal
pain.
Conclusion
MMF seems to be effective and safe in jo-SLE, especially in
patients without renal involvement. SLEDAI scores were
significantly reduced at 6 and 12 months; p < 0.05.
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